期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Neoadjuvant therapy in resectable pancreatic cancer:A promising curative method to improve prognosis
1
作者 Hao-Qi Zhang Jing Li +3 位作者 Chun-Lu Tan Yong-Hua Chen Zhen-Jiang Zheng Xu-Bao Liu 《World Journal of Gastrointestinal Oncology》 SCIE 2022年第10期1903-1917,共15页
Currently,15 randomized controlled trials(RCTs)have been designed to investigate whether neoadjuvant therapy(NAT)benefits patients with resectable pancreatic adenocarcinoma(R-PA)compared to surgery alone.Five of them ... Currently,15 randomized controlled trials(RCTs)have been designed to investigate whether neoadjuvant therapy(NAT)benefits patients with resectable pancreatic adenocarcinoma(R-PA)compared to surgery alone.Five of them have acquired results so far;however,corresponding conclusions have not been obtained.We speculated that the reason for this phenomenon could be that some prognostic factors had proven to be adverse through upfront surgery curative patterns,but some of them were not regarded as independent baseline characteristics,which is important to obtaining comparability between the NAT and upfront surgery groups.This fact could cause bias and lead to the difference in the outcomes of RCTs.In this review,we collate data about risk factors(such as tumor size,resection margin,and lymph node status)influencing the prognoses of patients with R-PA from five RCTs and discuss the possible reasons for the varying outcomes. 展开更多
关键词 Neoadjuvant therapy Resectable Pancreatic cancer PROGNOSIS
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部